18F-FES PET/CT in Imaging Patients With Desmoid Tumors

Pilot Investigation of 18F-FES PET/CT Imaging of Desmoid Tumors

This pilot clinical trial studies fluorine (F)-18 16 alpha-fluoroestradiol (18F-FES) positron emission tomography (PET)/computed tomography (CT) in imaging patients with desmoid tumors. 18F-FES binds to estrogen receptors, which are present on desmoid tumors, and gives off radiation that may be detected by PET and CT scans. The PET/CT scan forms an image that may show where tumor cells with estrogen receptors can be found in the body.

PRIMARY OBJECTIVES:

I. Establish the avidity of desmoid tumors on 18F-FES PET/CT imaging. II. Correlate 18F-FES PET avidity with degree of estrogen receptor (ER) expression by immunohistochemistry (IHC).

OUTLINE:

Patients undergo 18F-FES PET/CT imaging over 30 minutes.

After completion of study, patients are followed up for 30 days.

Inclusion Criteria:

• Patients with biopsy-proven extra-abdominal desmoid tumors
• Not currently on estrogen medication for birth control, menopause, or other reason
• No anti-estrogen therapy for desmoid tumor within the past 6 months
• Both sporadic desmoid tumors and those associated with familial adenomatous polyposis (FAP) syndromes will be included

Exclusion Criteria:

• Pregnancy or nursing patients
• Patients who do not wish to participate